


Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.


1. (Cancelled)
2. (Currently Amended) A compound of formula (I),



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

R¹ is C₁₋₆alkyl

R² is hydrogen or hydroxy or taken together with R⁴ may form =O;

R⁴ is hydrogen, C₁₋₆alkyl, furanyl, pyridinyl, arylC₁₋₆alkyl or  ;

n is 0 or 1;

X is N or CR⁵, wherein R⁵ is hydrogen;



R³ is -(CH₂)₈- NR⁶R⁷ or is (c-4) ;

s is 0, 1 or 2;

R⁶ is -CHO, C₁₋₆alkyl, piperidinylC₁₋₆alkyl, arylcarbonylpiperidinylC₁₋₆alkyl or arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl;

R⁷ is hydrogen or C₁₋₆alkyl;

and each R¹⁰ independently is hydrogen, C₁₋₆alkyl or C₁₋₆alkyloxyC₁₋₆alkylamino,

aryl is phenyl or phenyl substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy;

with the proviso that when



n is 0, X is N, R² is hydrogen, R³ is hydrogen; then

R⁴ is other than C₁₋₆alkyl or pyridinyl.

3. (Previously Presented) A compound according to claim 2 wherein

n is 0; X is N or CR⁵, wherein R⁵ is hydrogen; R¹ is C₁₋₆alkyl;

R² is hydrogen or hydroxy or taken together with R⁴ may form =O; R³ is -(CH₂)_s-NR⁶R⁷;

s is 0 or 1; R⁶ is -CHO or C₁₋₆alkyl; and R⁴ is hydrogen, C₁₋₆alkyl or



4. (Previously Presented) A compound selected from the group consisting of:

<p style="text-align: center;">compound 1</p>	<p style="text-align: center;">compound 5</p>
<p style="text-align: center;">compound 7</p>	<p style="text-align: center;">compound 3</p>
<p style="text-align: center;">compound 17</p>	

and the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.


5. (Cancelled)

6. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 2.


7. -11. (Cancelled).

12. (Currently Amended) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of formula (I) according to Claim 2.


13. (Previously Presented) A process for preparing a compound as claimed in claim 2, comprising: a) hydrolysis of intermediates of formula (VIII),



b) cyclization of intermediates of formula (X),



or c) condensation of an ortho-benzenediamine of formula (XI) with an ester of formula (XII) wherein R^h is C_{1-6} alkyl, into compounds of formula (I), wherein X is N, herein referred to as compounds of formula (I-i),



14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.

16. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.


17. - 26. (Cancelled)

27. (Currently Amended) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of claim 3.

28. (Currently Amended) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of claim 4.

29. - 30. (Cancelled)

31. (Currently Amended) A compound selected from



and the *N*-oxide forms and the pharmaceutically acceptable addition salts thereof.

32. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 31.

33. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 31.